{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:22:17Z","timestamp":1788585737007,"version":"build-2803163510"},"reference-count":40,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2020,6,30]]},"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1136\/ejhpharm-2020-002347","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T17:26:04Z","timestamp":1599153964000},"page":"182-189","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4936-2064","authenticated-orcid":false,"given":"Chen","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jie-Xin","sequence":"additional","affiliation":[{"name":"wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"2025090702565842000_28.4.182.1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1109\/TMI.2016.2642839","article-title":"Automated melanoma recognition in dermoscopy images via very deep residual networks","volume":"36","author":"Yu","year":"2017","journal-title":"IEEE Trans Med Imaging"},{"key":"2025090702565842000_28.4.182.2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1147\/JRD.2017.2708299","article-title":"Deep learning ensembles for melanoma recognition in dermoscopy images","volume":"61","author":"Codella","year":"2017","journal-title":"IBM J Res Dev"},{"key":"2025090702565842000_28.4.182.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112302"},{"key":"2025090702565842000_28.4.182.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"2025090702565842000_28.4.182.5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/PAI.0000000000000013","article-title":"BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression","volume":"22","author":"Ehsani","year":"2014","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"2025090702565842000_28.4.182.6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2915"},{"key":"2025090702565842000_28.4.182.7","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1007\/s00216-017-0316-8","article-title":"Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma","volume":"409","author":"Vikingsson","year":"2017","journal-title":"Anal Bioanal Chem"},{"key":"2025090702565842000_28.4.182.8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2217\/pgs.16.4","article-title":"Pyrexia in dabrafenib-treated melanoma patients is not associated with common genetic variation or HLA polymorphisms","volume":"17","author":"Kulkarni","year":"2016","journal-title":"Pharmacogenomics"},{"key":"2025090702565842000_28.4.182.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.08.022"},{"key":"2025090702565842000_28.4.182.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70007-5"},{"key":"2025090702565842000_28.4.182.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60398-5"},{"key":"2025090702565842000_28.4.182.12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12253-017-0256-9","article-title":"Dabrafenib therapy in 30 patients with melanoma metastatic to the brain: a single-centre controlled retrospective study in Hungary","volume":"24","author":"Gorka","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"2025090702565842000_28.4.182.13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/CMR.0000000000000036","article-title":"A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme","volume":"24","author":"Lau","year":"2014","journal-title":"Melanoma Res"},{"key":"2025090702565842000_28.4.182.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.8691"},{"key":"2025090702565842000_28.4.182.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70431-X"},{"key":"2025090702565842000_28.4.182.16","doi-asserted-by":"crossref","first-page":"105000","DOI":"10.18632\/oncotarget.21072","article-title":"Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E\/K mutation","volume":"8","author":"Momtaz","year":"2017","journal-title":"Oncotarget"},{"key":"2025090702565842000_28.4.182.17","first-page":"1020","article-title":"BREAK-2: a phase IIA trial of the selective BRAF kinase inhibitor GSK2118436 in patients with BRAF (V600E\/K)-positive metastatic melanoma [abstract]","volume":"24","author":"Trefzer","year":"2011","journal-title":"Pigm Cell Melanoma R"},{"key":"2025090702565842000_28.4.182.18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10637-017-0502-8","article-title":"Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study","volume":"36","author":"Fujiwara","year":"2018","journal-title":"Invest New Drugs"},{"key":"2025090702565842000_28.4.182.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0887"},{"key":"2025090702565842000_28.4.182.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11155.x"},{"key":"2025090702565842000_28.4.182.21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu154"},{"key":"2025090702565842000_28.4.182.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60868-X"},{"key":"2025090702565842000_28.4.182.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60898-4"},{"key":"2025090702565842000_28.4.182.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.3535"},{"key":"2025090702565842000_28.4.182.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"},{"key":"2025090702565842000_28.4.182.26","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000009523","article-title":"Dabrafenib plus trametinib for compassionate use in metastatic melanoma: a STROBE-compliant retrospective observational postauthorization study","volume":"96","author":"Mart\u00edn Algarra","year":"2017","journal-title":"Medicine"},{"key":"2025090702565842000_28.4.182.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708539"},{"key":"2025090702565842000_28.4.182.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30171-7"},{"key":"2025090702565842000_28.4.182.29","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"2025090702565842000_28.4.182.30","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14210"},{"key":"2025090702565842000_28.4.182.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01435.x"},{"key":"2025090702565842000_28.4.182.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.06.002"},{"key":"2025090702565842000_28.4.182.33","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.118"},{"key":"2025090702565842000_28.4.182.34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth","year":"2014","journal-title":"Australas J Dermatol"},{"key":"2025090702565842000_28.4.182.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04060.x"},{"key":"2025090702565842000_28.4.182.36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/15569527.2018.1553180","article-title":"The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis","volume":"38","author":"Chen","year":"2019","journal-title":"Cutan Ocul Toxicol"},{"key":"2025090702565842000_28.4.182.37","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bjd.13958","article-title":"Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations","volume":"173","author":"Sinha","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025090702565842000_28.4.182.38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/02841860903104152","article-title":"Case studies showing clinical signs and management of cutaneous toxicity of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours","volume":"49","author":"Desar","year":"2010","journal-title":"Acta Oncol"},{"key":"2025090702565842000_28.4.182.39","first-page":"300","article-title":"[Hand-foot syndrome after administration of tyrosinkinase inhibitors]","volume":"23","author":"Bednar\u00edkov\u00e1","year":"2010","journal-title":"Klin Onkol"},{"key":"2025090702565842000_28.4.182.40","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/ced.13751","article-title":"Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma","volume":"44","author":"Chen","year":"2019","journal-title":"Clin Exp Dermatol"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2020-002347","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:57:06Z","timestamp":1757239026000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2020-002347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,6,23]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/ejhpharm-2020-002347"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2020-002347","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]}}}